AEGIS-II Misses Primary Endpoint, Suggests Potential for CSL112 in Hyperlipidemia
CSL112 infusion did not reduce major cardiovascular events at 90 days but further analysis suggests patients with elevated LDL-C levels could derive significant benefit.
Source: hcplive.com